Scarica l'app Stockscreener
42.86
2.12%
0.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$41.97
Aprire:
$41.61
Volume 24 ore:
1.33M
Relative Volume:
0.83
Capitalizzazione di mercato:
$4.07B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-11.49
EPS:
-3.73
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
+0.45%
1M Prestazione:
+0.02%
6M Prestazione:
+43.11%
1 anno Prestazione:
-24.85%
Intervallo 1D:
$41.51
$43.77
Intervallo di 1 settimana:
$41.51
$45.16
Portata 52W:
$24.10
$60.34
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Confronta CRNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
42.86 | 3.98B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
What technical signals suggest for Crinetics Pharmaceuticals Inc. stockTake Profit & Risk Controlled Stock Pick Alerts - newser.com
United States Congenital Adrenal Hyperplasia Treatment - openPR.com
Can Crinetics Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe haven assetPortfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockGlobal Markets & High Return Stock Watch Alerts - newser.com
Price-Driven Insight from (CRNX) for Rule-Based Strategy - news.stocktradersdaily.com
Crinetics begins Phase 3 trial of oral therapy for carcinoid syndrome - Investing.com Nigeria
Crinetics Pharmaceuticals Begins Phase 3 Trial of Paltusotine in Carcinoid Syndrome - MarketScreener
Crinetics (CRNX) Begins Phase 3 Trial for Paltusotine Treatment - GuruFocus
Crinetics announces first patient randomized in pivotal phase 3 CAREFNDR trial evaluating paltusotine in carcinoid syndrome - MarketScreener
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome - The Manila Times
Crinetics Pharmaceuticals Advances Phase 3 CAREFNDR Trial for Paltusotine in Treating Carcinoid Syndrome - Quiver Quantitative
Crinetics (Nasdaq: CRNX) Starts Phase 3 CAREFNDR Trial for 141 Carcinoid Patients - Stock Titan
Using data tools to time your Crinetics Pharmaceuticals Inc. exit2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.Entry Point & High Accuracy Swing Trade Signals - newser.com
Why Crinetics Pharmaceuticals Inc. (6Z4) stock attracts HNW investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock cheap by valuation metricsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Is Crinetics Pharmaceuticals Inc. stock a safe buy before earningsQuarterly Trade Report & Risk Adjusted Buy/Sell Alerts - newser.com
Is Crinetics Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Closing Moves & Daily Momentum Trading Reports - newser.com
Crinetics Pharmaceuticals Inc.’s volatility index tracking explained2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Can Crinetics Pharmaceuticals Inc. rally from current levels2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
What institutional flow reveals about Crinetics Pharmaceuticals Inc. - newser.com
Is Crinetics Pharmaceuticals Inc. (6Z4) stock supported by free cash flowMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
Quantitative breakdown of Crinetics Pharmaceuticals Inc. recent moveJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
Automated trading signals detected on Crinetics Pharmaceuticals Inc.Long Setup & AI Enhanced Market Trend Forecasts - newser.com
Will Crinetics Pharmaceuticals Inc. stock deliver better than expected guidance2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Chart based analysis of Crinetics Pharmaceuticals Inc. trendsMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Crinetics Pharmaceuticals Inc.2025 Year in Review & Free Expert Verified Stock Movement Alerts - newser.com
Backtesting results for Crinetics Pharmaceuticals Inc. trading strategiesStop Loss & Long-Term Safe Investment Ideas - newser.com
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):